Close this search box.

Zurich Executive Summit: Unveiling the Future of Cannabis-Pharmaceutical Collaboration

The European cannabis events season is now in full swing, and this month all eyes are turning to Switzerland, one of the most exciting cannabis markets on the continent, now set to host some of its most exciting conferences.

On May 23, 2024, Business of Cannabis is launching its latest annual leadership summit in the heart of Zurich, set to bring together a diverse array of leaders from both the pharmaceutical and cannabis industries, along with public health policymakers and investors, for a groundbreaking exploration of their intersection.

Just a day after the Zurich Executive Summit, the international hemp fair CannaTrade will welcome more than 150 exhibitors from across the world to Halle 622, Zurich-Oerlikon. This two day event, taking place from May 24 to May 26, will focus on everything from Switzerlands’s flourishing pilot projects, to cultivation recommendations for German growers’ associations.

The Zurich Executive Summit, taking place at 4pm at the Zunfthaus zur Zimmerleuten Restaurant, will provide a groundbreaking exploration of the intersection between the cannabis and pharmaceutical industries, promising to provide a deep dive into the evolving dynamics between these two sectors and their potential convergence in the near future.

Amidst growing interest and investment in both medical cannabis and the country’s flourishing adult-use pilot projects, the summit will feature insights from leading cannabis and pharmaceutical companies, including Linnea, Cannavigia, Brains Biocutical and Dascoli Pharma. 

The summit agenda includes a concise 3-hour program designed to provide attendees with valuable knowledge and connections. The event will culminate in a high-level networking drink reception, offering participants a chance to forge new partnerships and collaborations.


Leading Swiss pharmaceutical manufacturer Linnea, one of the first companies in the world to obtain full GMP accreditation for CBD isolate, is set to kick off the day’s agenda with an exploration of how to develop pharmaceutical grade cannabinoids.

“The cannabinoid regulatory pathway is different from the other active substances for pharmaceutical purposes,” Linnea said.

“Coming from the bottom, pushed by patients asking for a new, safe, and effective solution for uncovered therapeutic needs, they are now being slowly aligned with the quality, safety and efficacy requirements described by international pharmaceutical rules.

“We decided from the beginning of our cannabinoids development to use the same standard we apply to the other active pharmaceutical ingredients, and this led us to get several registrations and maintain them, support several severe disease clinical settings, partner with important universities worldwide, and influence, in our opinion, the regulatory pathway raising now in Europe.”

The evening’s presentations will conclude with an exploration of the ‘possibilities in Switzerland’ from Dascoli Pharma. 

“Since the early 20th Century, Switzerland has been synonymous with pharmaceutical innovation and global reach,” the Swiss pharmaceutical firm said.

“With the recent expansion of medical cannabis prescription possibilities, rising sector interest from Pharma and institutional capital, and a patient base uniquely primed for herbal medicines – Switzerland remains intricately positioned to present the high-water-mark of medical cannabis patient access, innovation and care.”

For more information, visit the event website, or book your tickets here. 


Related Posts

Related Posts


Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you


Browse by Tags




© 2023 Prohibition Holdings Ltd. All Rights Reserved.


Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?